V Bryan Lawlis
CIK 1247681 · last filed 2025-05-22
V Bryan Lawlis is a corporate insider who has filed 81 SEC Form 4 insider transactions across 6 companies since 2007. The most recent filing, for GERN, was dated May 22, 2025. Across all open-market trades the lifetime net is −$9.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.9M across reported positions. 50 SEC filings were submitted jointly with BIOMARIN PHARMACEUTICAL INC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
BMRN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| GERN | Director | 13,300 | $1.13 | $15.0K | -$220.6K | 16 | 2025-05-22 |
| BMRN | Director | 33,140 | $56.63 | $1.88M | -$9.28M | 45 | 2023-05-24 |
| Spyre Therapeutics, Inc. (AGLE) Delisted | Director | — | $12.01 | — | $0 | 5 | 2022-06-09 |
| CHRS | Director | — | $1.05 | — | $0 | 10 | 2021-01-13 |
| STRO | Director | — | $10.29 | — | $0 | 1 | 2018-09-27 |
| HUMANIGEN, INC (KBIO) Delisted | Director | — | — | — | $0 | 1 | 2013-09-03 |
Recent Filings
81 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-05-22 | GERN | Grant (A) | — | $0 | EDGAR |
| 2025-05-13 | GERN | Buy (P) | +13,300 | $15.7K | EDGAR |
| 2024-05-30 | BMRN | Notice (144) | −6,600 | -$496.3K | EDGAR |
| 2024-05-17 | GERN | Mixed | — | -$63.4K | EDGAR |
| 2024-05-15 | GERN | Notice (144) | −35,000 | -$131.3K | EDGAR |
| 2024-05-10 | GERN | Grant (A) | — | $0 | EDGAR |
| 2023-06-02 | GERN | Grant (A) | — | $0 | EDGAR |
| 2023-05-24 | BMRN | Grant (A) | +4,190 | $0 | EDGAR |
| 2023-05-11 | GERN | Notice (144) | −35,000 | -$105.0K | EDGAR |
| 2023-05-11 | GERN | Mixed | — | -$66.5K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.